2013 SPEAKER BIOS
Michelle L. Basil is a partner in the Business Department of Nutter, a member of the firm’s Emerging Companies practice group and chair of the Life Sciences practice group. Michelle’s practice focuses on corporate and securities law, including angel and venture capital transactions, public securities offerings, mergers and acquisitions, strategic partnerships and collaborations, licensing, distribution transactions and corporate governance, and equity compensation matters. Michelle represents clients in a broad range of industries, including public and private life sciences, high technology and financial services companies. Michelle serves as outside general counsel to companies in biotechnology, medical devices, diagnostics, and health care services. Michelle received her B.A. and J.D. from the University of California, Berkeley. Michelle is a member of or participates at Boston Harbor Angels, M2D2, MTTC, Launchpad Venture Group, MassBio and MassMEDIC.
Barbara S. Fox, Ph.D., is founder and CEO of Avaxia Biologics, a leader in the growing field of gut-targeted therapeutics. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This product offers potentially improved safety and efficacy by focusing immune suppression only where needed in the inflamed gut. Avaxia has raised $15.5M in equity capital, primarily from angel investors, and $5.8M in non-dilutive funding. Dr. Fox’s previous positions have included Affiliated Entrepreneur at Oxford Bioscience Partners; founder, President, and Chief Scientific Officer of Recovery Pharmaceuticals; Vice President, Discovery and Immunology at ImmuLogic Pharmaceutical Corp.; and Associate Professor of Rheumatology and Clinical Immunology at the University of Maryland School of Medicine. Dr. Fox received her Ph.D. in Chemistry from MIT and trained as a post-doc in cellular immunology at the NIH.
Henry Kay is the U.S. Partner of Medica Venture Partners, a healthcare dedicated VC based in Israel and is an active member of two Angel Investing Groups (Boston Harbor Angels and Launchpad).
He retired from Boston Scientific in 2006, where he was Group Vice President of New Market Development / Strategic Planning, Endosurgery Boston Scientific Corporation (BSC).
Prior to joining BSC, Henry was based in the UK for five years as Senior Vice President, Sales and Marketing for Allergan Europe, a global eye care company. He has 35 years of experience in the medical industry in roles which include R&D, International Marketing, Regulatory Affairs, and Strategic Planning for major pharmaceutical companies, including Schering-Plough, American Home Products, Sterling Drug and Allergan.
Henry is a fellow of the Royal Society of Medicine (UK). He serves on the Boards of several start up health care companies, including Smart Cells (sold to Merck in 2010), Cool Systems, Avaxia, Christcot Medical, and Cannuflow. He was a member of the Board of Directors of Microfluidics, a public company in the equipment space for pharmaceutical manufacture (sold to IDEX in 2010). Internationally, he serves on the boards of 3 Canadian Medical Device companies (Cellaegis Devices and Imagistx in Toronto and Dartmouth Medical Research in Halifax). He has been a mentor with the Venture Mentoring Service of MIT. He serves on the Board of Overseers of Beth Israel-Deaconess and Newton Wellesley Hospitals. In addition, he is serving on the boards of Neurofibromatosis (NF Inc.) and JF&CS, both non profit organizations.
Henry holds Bachelors (Augusta College) and Master’s Degrees in Chemistry from Rutgers University, and an MBA in International Marketing from Seton Hall University. Henry is a past President of Temple Beth Elohim in Wellesley, Massachusetts. Henry and his wife Laurie have one grown daughter and reside in Weston, Massachusetts.
Stephen Kraus, a partner in the Cambridge, Mass. office, has worked with Bessemer since 2004 and focuses on the healthcare sector. Currently, he focuses his new deal activity on early and growth stage opportunities in healthcare IT and healthcare services.
He currently sits on the boards of Liazon, Health Essentials, DocuTAP, Ovascience, (NASDAQ: OVAS), Allena Pharmaceuticals and Alcresta and is actively involved in BVP’s investments in Acceleron (NASDAQ: XLRN) and Proteon. Steve has been actively involved in Bessemer’s investments in Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by GlaxoSmithKline); Affymax (NASDAQ: AFFY); AVEO (NASDAQ: AVEO); Alnara, acquired by Eli Lilly; Transave (NASDAQ: INSM); Stromedix, acquired by Biogen Idec, Verastem (NASDAQ: VSTM), and Restore Medical (NASDAQ: REST), acquired by Medtronic.
Prior to joining Bessemer, Steve was a director at the Ironwood Equity Fund, a growth-stage, private-equity firm, and a management consultant at Bain & Co. In 2002, he served as speechwriter and operations director for the Democratic nominee for governor of Massachusetts.
Steve graduated summa cum laude with a B.A. from Yale University and earned his MBA from Harvard, where he was a Baker Scholar. He serves on the boards of the New England Venture Capital Association (NEVCA), the Achievement Network, and Interise. Steve was recently recognized by Forbes Magazine as one of the top life science investors in 2013.
Steve regularly blogs with BVP’s Ambar Bhattacharyya at HCVC’s (two healthcare investors’ musings on work and life).
Jonathan Norris is a managing director with SVB Capital’s Venture Capital Relationship Management team, specializing in life sciences. Norris oversees strategic relationships with select life science venture capital firms on the West Coast, sourcing and advising on direct equity co-investment, limited partnership, and portfolio company banking and lending opportunities. In addition, he helps life science companies with equity fundraising strategy. Norris has more than eleven years of banking experience working with life science companies and venture capital firms.
Prior to joining SVB Capital, Norris was a founding member and senior vice president of Square 1 Bank, an early stage technology bank, where he was an account officer responsible for sourcing deals and managing regional and national venture capital relationships. Norris also served more than six years at Imperial Bank (subsequently acquired by Comerica Bank), most recently as senior vice president and group manager of the Northern California Life Science Practice. Prior to banking, Norris was a practicing litigation attorney, specializing in employment defense and toxic tort litigation. Norris earned a bachelor’s degree in business administration from the University of California, Riverside and a JD from Santa Clara University.
Michael Powell has more than 25 years of pharmaceutical development experience, and he has focused interest in clinical-stage product companies, particularly in the oncology, endocrine, and neurology areas. He joined Sofinnova Ventures as a General Partner in 1997 as a member of the Life Science investment team. Prior to becoming a venture capitalist, Mike worked on 20 clinical products and authored almost 100 papers and books, including an 1,000–page treatise on vaccine design. Mike was the initial investor in: Actelion (SWX: ATLN), InterMune (Nasdaq: ITMN), Anesiva (Nasdaq: ANSV), Orexigen Therapeutics (Nasdaq: OREX), Seattle Genetics (Nasdaq: SGEN), Threshold Pharmaceuticals (Nasdaq: THLD), and Trius Therapeutics (Nasdaq: TSRX), as well as several private companies such as: Alvine, Ascenta and Intellikine (acquired by Millennium/Takeda).
Mike is currently Board President of AVAC (AIDS Vaccine Advocacy Coalition) in NYC, a past Advisor to the Bill and Melinda Gates Foundation, a past Strategic Advisor to One World Health, and a Founding Venture Advisory Board member of the IAVI (International AIDS Vaccine Initiative) Innovation Fund. He also serves on the University of Kansas board of IAMI (Institute for the Advancement of Medical Innovation), and the University of Minnesota’s CPD (Committee for Pharmaceutical Development). Mike was Group Leader of Drug Delivery at Genentech (1990–97) where his focus was developing new therapeutics. In 1987 he was part of the founding team of Cytel; as Director of Product Development he was responsible for the company’s early growth which culminated in a successful IPO. Before this he was Scientist and Project Team Leader at Syntex Research. Mike had the honor of being the first scientist from the biotechnology industry to be elected a Fellow of the American Association of Pharmaceutical Scientists. He was also an Adjunct Professor at the University of Kansas, an Editorial Board member of J. Pharm. Sci., and a Scientific Advisor to the Controlled Release Society.
He received his PhD in Physical Chemistry from the University of Toronto in 1981, and completed his post-doctorate work in Bioorganic Chemistry at the University of California, where he was subsequently a faculty member (1981–84).
Laurel Sweeney is the Senior Director for the Global Health Economics and Reimbursement function at Philips Healthcare, one of the largest medical technology companies in the world. As a Reimbursement and Health Policy Executive, she has deep expertise in health policy, medical technology, and global health systems and reimbursement policies. In her current role, she focuses on market access and routine optimal payments for a wide range of medical technologies and services. With the numerous changes occurring under global healthcare reform, she is able to leverage her background in communications, lobbying and reimbursement policy to enable Philips and its customers to respond to ongoing changes in the market.
Throughout her career, she has gained extensive knowledge of global healthcare markets, built a valuable network, and developed personal relationships with providers, payers, and policy makers. This allows her to identify and partner with the appropriate stakeholders to meet policy and reimbursement objectives.